The tumor necrosis factor receptor superfamily members 4 (TNFRSF4, OX40) and 18 (TNFRSF18, GITR, AITR) have been under investigation as potential targets for the immunotherapy of various cancers, including HNSCC [49,50]. This evidence concerns the gene TNFRSF18 and cancer.